U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07208773) titled 'A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors' on Sept. 28.
Brief Summary: This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Non Small Cell Lung Cancer
Small Cell Lung Cancer
Intervention:
DRUG: YL201
YL201 will be administered as IV infusion
DRUG: Ivonescimab
Ivonescimab will be administered as IV infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Disclaimer: Curated by HT Syndic...